Qianhai Health Holdings (HKSE:00911) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Qianhai Health Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Qianhai Health Holdings is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Qianhai Health Holdings's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qianhai Health Holdings's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Qianhai Health Holdings's Risk Assessment falls into.

Qianhai Health Holdings (HKSE:00911) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Qianhai Health Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Qianhai Health Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Qianhai Health Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qianhai Health Holdings Ltd (HKSE:00911) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

177-183 Wing Lok Street, Room 301-3, 3rd Floor, Wing Tuck Commercial Centre, Sheung Wan, Hong Kong, HKG

Website

https://www.qianhaihealth.com.hk

Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products and the sale of information technology components products. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products includes sale of healthcare products including Chinese herbal medicines, skincare and other healthcare products. Electronic component products includes sale of information technology components products including central processing unit and semiconductors. The group's revenue is all derived from Hong Kong.

Executives

Chong Siew Hoong	2202 Interest of your spouse
Explorer Rosy Limited
Hou Chung Man	2501 Other
Huang Zhiqun
Huang Guanchao	2101 Beneficial owner
Shinewing Sas (nominee Services) No. 3 Limited	2501 Other
Tang Chung Wah	2501 Other
Sparkling Rock Limited	2201 Interest of corporation controlled by you
Lim Tzea	2101 Beneficial owner
Great Prosperous Limited
Noble Stand Global Limited
Thousands Beauties Limited
Yunnan Energy Investment (h K) Co. Limited	2106 Person having a security interest in shares
Yunnan International Holding Group Limited	2106 Person having a security interest in shares
Yunnan International Supply Chain Limited	2106 Person having a security interest in shares

Qianhai Health Holdings Headlines

No Headlines